Morgan Stanley raises MKS Instruments price target on NAND outlook By Investing.com

Morgan Stanley raised its MKS Instruments price target to $374 from $354 and kept an Overweight rating, lifting its fiscal 2027 EPS estimate to $17.01 from $16.07 and revenue forecast to $5.82 billion from $5.63 billion. The firm also boosted its 2027 NAND WFE forecast to $24.0 billion from $19.7 billion, citing tighter EUV supply and incremental memory clean-room capacity, which supports higher semiconductor equipment demand. Upside is partially offset by risks from consumer electronics weakness and DRAM/logic exposure.

Analysis

The key second-order read is that this is not just an AMAT/LRCX demand story; it is a mix-shift story inside WFE where NAND becomes the marginal growth engine while front-end logic/DRAM likely stay softer. That matters because NAND capex is more cyclical and can reaccelerate sharply once customers de-bottleneck clean-room capacity and lock in long-lead tooling, creating a multi-quarter order step-up rather than a single-quarter beat. For suppliers with RF power and etch exposure, the operating leverage is unusually high because a modest recovery in NAND share of revenue can disproportionately expand margins after the 2022-2024 downcycle.

AMAT is the cleaner expression of the broader equipment upcycle because it benefits from both visibility and breadth: guidance momentum, analyst revisions, and exposure to multiple process steps reduce single-end-market risk. LRCX is a more levered but more fragile way to express the same thesis; if NAND spending normalizes, Lam can outperform on beta, but it will also underperform faster if consumer electronics weakens or DRAM/logic spending rolls over. The hidden winner may be the supply chain around high-aspect-ratio etch and power delivery, where vendors with embedded content can see share gains even before unit growth fully inflects.

The contrarian risk is that the market may be extrapolating 2027 spend into 2025-2026 multiples too aggressively. If consumer demand remains soft, customers can delay tools despite long-term agreements, which would turn the current estimate revision cycle into a timing issue rather than a magnitude issue. Also, if EUV constraints ease or memory makers choose to prioritize DRAM over NAND, the assumed NAND-led mix improvement could disappoint within 2-3 quarters.

For MS, the setup is more nuanced: the stock is not the obvious semiconductor beta trade, but it has convexity if NAND share of semiconductor revenue mean-reverts toward prior levels. The recovery path into 2026 suggests the market may still be underpricing the earnings leverage from a modest share reversion, while the valuation discount to front-end peers leaves room for multiple expansion if the recovery proves durable.

Key Decisions for Investors

• Go long AMAT vs. SOX over the next 3-6 months; it has the best risk-adjusted exposure to the current capex revision cycle and lower single-end-market fragility. Target 8-12% relative upside with tighter drawdown than LRCX.
• Initiate a tactical long LRCX position only on weakness, sized smaller than AMAT, for a 2-4 quarter trade on NAND reacceleration. Use a 12-15% stop because the name will be more sensitive if memory spending pauses.
• Buy MS on pullbacks as a delayed-beneficiary recovery play into FY26-FY27, ideally paired against a front-end equipment basket. The setup is a catch-up trade if NAND share normalizes, with 20%+ upside if the market starts to price the revised earnings power.
• Pair long AMAT / short a basket of more consumer-exposed semiconductor hardware names over 1-2 quarters. The thesis is that broad equipment strength is real, but names with weaker end-demand mix should lag if the capex upturn stays concentrated in NAND.
• Avoid chasing the move into the print; wait for either a brief sector-wide risk-off day or a confirmation quarter from another major tool vendor. The upside is better once consensus revisions broaden beyond one or two leaders.